2017
CNS Leukemia
An Y, Roberts K. CNS Leukemia. 2017, 311-333. DOI: 10.1007/978-3-319-55430-3_17.Peer-Reviewed Original ResearchAcute myeloid leukemiaAcute lymphoblastic leukemiaAllogeneic stem cell transplantCentral nervous system involvementPediatric acute lymphoblastic leukemiaInduction systemic therapyHigh-risk patientsNervous system involvementTotal body irradiationStem cell transplantUse of radiotherapyHigh cure ratesIntensity of therapyBlood-brain barrierCNS leukemiaCNS relapseCNS lymphomaPalliative therapySystemic therapyPrognostic factorsBody irradiationCell transplantRisk stratificationCure rateCommon cancer
2016
A Novel Prognostic Index for Ocular Adnexal Lymphoma
Meeks M, Park H, Yu J, Roberts K, Foss F, Wilson L. A Novel Prognostic Index for Ocular Adnexal Lymphoma. Blood 2016, 128: 3597. DOI: 10.1182/blood.v128.22.3597.3597.Peer-Reviewed Original ResearchOcular adnexal lymphomaNovel prognostic indexOverall survivalIndolent histologiesPrognostic indexRelative survivalAdnexal lymphomaGroup IIGroup IGroup I. Group IEnd Results (SEER) databaseSuperior overall survivalCohort of patientsProportional hazards analysisKaplan-Meier estimatesLacrimal gland tumorsHeterogeneous patient populationLarge national databaseAggressive histologyDistant diseaseConjunctival tumorsHazard ratioPrognostic factorsRare malignancyIndependent predictorsACR Appropriateness Criteria® Hodgkin Lymphoma—Unfavorable Clinical Stage I and II
Roberts KB, Younes A, Hodgson DC, Advani R, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Constine LS. ACR Appropriateness Criteria® Hodgkin Lymphoma—Unfavorable Clinical Stage I and II. American Journal Of Clinical Oncology 2016, 39: 384-395. PMID: 27299425, DOI: 10.1097/coc.0000000000000294.Peer-Reviewed Original ResearchConceptsHodgkin's lymphomaAppropriateness CriteriaEvidence-based treatment algorithmEarly-stage Hodgkin lymphomaAppropriateness of imagingClinical stage IRadiation treatment volumesMajor clinical trialsACR Appropriateness CriteriaRadiology Appropriateness CriteriaMultidisciplinary expert panelEvidence-based guidelinesClassic Hodgkin lymphomaInvolved-site radiotherapySpecific clinical conditionsCurrent medical literatureAppropriate treatment decisionsLong-term toxicityCurrent treatment schemesRadiation dose prescriptionUnfavorable presentationSequential chemotherapyPeer-reviewed journalsPrognostic factorsTherapy intensity
2013
ACR Appropriateness Criteria: Localized nodal indolent lymphoma.
Hoppe BS, Hodgson DC, Advani R, Dabaja BS, Flowers CR, Ha CS, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Terezakis SA, Winkfield KM, Younes A, Constine LS. ACR Appropriateness Criteria: Localized nodal indolent lymphoma. Oncology 2013, 27: 786-94. PMID: 24133827.Peer-Reviewed Original ResearchConceptsIndolent lymphomaAppropriateness of imagingOutcomes of patientsMultidisciplinary expert panelRadiology Appropriateness CriteriaEvidence-based guidelinesSpecific clinical conditionsCurrent medical literatureAppropriate treatment decisionsPeer-reviewed journalsPrognostic factorsTreatment optionsAppropriateness CriteriaTreatment decisionsClinical conditionsAmerican CollegeGuideline developmentMedical literatureRadiation guidelinesConsensus methodologyLymphomaExpert panelRadiation dosePatientsRadiation techniques